Clay B. Siegall Buys 150,000 Shares of Immunome, Inc. (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) CEO Clay B. Siegall bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the purchase, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at $5,189,679. This represents a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Immunome Stock Down 6.4 %

IMNM stock traded down $0.71 during mid-day trading on Monday, hitting $10.32. 1,122,794 shares of the company were exchanged, compared to its average volume of 1,001,049. The business has a fifty day simple moving average of $11.34 and a 200-day simple moving average of $12.68. Immunome, Inc. has a 12-month low of $8.97 and a 12-month high of $30.96. The firm has a market capitalization of $644.17 million, a P/E ratio of -1.27 and a beta of 1.90.

Analyst Upgrades and Downgrades

IMNM has been the subject of a number of recent research reports. Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Monday, January 13th. Stephens assumed coverage on Immunome in a research report on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock. Finally, Piper Sandler reduced their price objective on Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome presently has an average rating of “Buy” and an average price target of $28.60.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. lifted its position in shares of Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after acquiring an additional 302,916 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Immunome by 48.1% during the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock valued at $10,684,000 after purchasing an additional 237,497 shares during the period. Geode Capital Management LLC grew its holdings in Immunome by 13.6% during the third quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after acquiring an additional 144,557 shares during the period. Magnus Financial Group LLC increased its stake in Immunome by 107.8% in the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock worth $569,000 after purchasing an additional 27,777 shares in the last quarter. Finally, Point72 Asset Management L.P. boosted its position in Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after acquiring an additional 85,580 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.